Penumbra (PEN) Total Non-Current Liabilities (2014 - 2026)
Penumbra (PEN) reported Total Non-Current Liabilities of $411.4 million for Q1 2026, up 12.87% year-over-year from $364.5 million in Q1 2025, and up 6.41% quarter-over-quarter from $386.6 million in Q4 2025.
Penumbra (PEN) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Total Non-Current Liabilities data on file, last reported at $411.4 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $411.4 million, up 12.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $411.4 million (up 12.87% YoY), and the FY2025 annual result was $386.6 million, up 5.3% from the prior year.
- Total Non-Current Liabilities improved to $411.4 million in Q1 2026 per PEN's latest filing, from $386.6 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $411.4 million in Q1 2026 and troughed at $338.7 million in Q1 2022.
- A 5-year average of $366.8 million and a median of $365.7 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities surged 85.68% in 2022, then fell 1.61% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $368.8 million in 2022, then climbed by 0.9% to $372.1 million in 2023, then slipped by 1.32% to $367.1 million in 2024, then grew by 5.3% to $386.6 million in 2025, then rose by 6.41% to $411.4 million in 2026.
- Business Quant data shows PEN's Total Non-Current Liabilities at $411.4 million in Q1 2026, $386.6 million in Q4 2025, and $371.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | - |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 40.52 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 15.78 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | 2.44 Bn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 24.21 Bn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 9.85 Bn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 3.53 Bn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 3.47 Bn |
| 10 | Penumbra | 12.51 Bn | 11.90 Bn | 253.41 Mn | 411.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 411.38 Mn |
| Dec 31, 2025 | 386.60 Mn |
| Sep 30, 2025 | 371.14 Mn |
| Jun 30, 2025 | 363.04 Mn |
| Mar 31, 2025 | 364.48 Mn |
| Dec 31, 2024 | 367.14 Mn |
| Sep 30, 2024 | 365.39 Mn |
| Jun 30, 2024 | 365.71 Mn |
| Mar 31, 2024 | 370.44 Mn |
| Dec 31, 2023 | 372.05 Mn |
| Sep 30, 2023 | 360.97 Mn |
| Jun 30, 2023 | 362.70 Mn |
| Mar 31, 2023 | 367.59 Mn |
| Dec 31, 2022 | 368.75 Mn |
| Sep 30, 2022 | 344.55 Mn |
| Jun 30, 2022 | 354.41 Mn |
| Mar 31, 2022 | 338.66 Mn |
| Dec 31, 2021 | 286.77 Mn |
| Sep 30, 2021 | 281.00 Mn |
| Mar 31, 2021 | 182.39 Mn |